评估尿路医疗器械抗菌与抗污材料的疗效:挑战与建议
欧洲重症监护病房尿路感染平均发病率为每1000患者日1.1例,其中导管相关尿路感染(CAUTI)占98%;仅英国医院CAUTI估计增加1-2.5亿英镑医疗费用,与泌尿导管低成本形成鲜明对比,凸显减少CAUTI发生率创新产品的需求。输尿管支架及其他尿路器械存在类似问题。抗菌策略正在开发中,但其疗效评估极具挑战性。本综述旨在提供抗菌材料测试所有相关方面的考量与建议,包括表面表征、生物相容性、细胞毒性、体外与体内试验、微生物菌株选择及流体力学条件,均以契合器械相关尿路感染复杂病理为视角。建议应基于待开发的标准检测方法,使工业界与学术界不同研究实验室获得的结果可比较,并为工业界和学术界提供可靠评估尿路器械抗菌性能的工具。
要点
- 欧洲ICU尿路感染平均发病率为每1000患者日1.1例,其中CAUTI占98%。
- 仅英国医院CAUTI估计增加1-2.5亿英镑医疗费用,与泌尿导管低成本形成鲜明对比。
- 输尿管支架及其他尿路器械存在与CAUTI类似的问题。
- 抗菌材料疗效评估极具挑战性,需覆盖表面表征、生物相容性、细胞毒性、体外与体内试验、菌株选择及流体力学条件。
- 建议基于待开发的标准检测方法,使不同研究实验室结果可比较,并为工业界与学术界提供可靠评估尿路器械抗菌性能的工具。
适用人群与场景
- 重症监护病房中发生尿路感染的患者,其中导管相关尿路感染(CAUTI)占98%。
- 使用输尿管支架及其他尿路器械并面临类似感染问题的患者。
研究设计与关键结果
- 本综述旨在提供抗菌材料测试所有相关方面的考量与建议,包括表面表征、生物相容性、细胞毒性、体外与体内试验、微生物菌株选择及流体力学条件,均以契合器械相关尿路感染复杂病理为视角。
- 建议应基于待开发的标准检测方法,使工业界与学术界不同研究实验室获得的结果可比较。
- 建议应为工业界和学术界提供可靠评估尿路器械抗菌性能的工具。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议抗菌材料测试应覆盖表面表征、生物相容性、细胞毒性、体外与体内试验、微生物菌株选择及流体力学条件,以契合器械相关尿路感染的复杂病理。
- 作者建议基于待开发的标准检测方法评估尿路器械抗菌性能,使不同研究实验室结果可比较,并为工业界和学术界提供可靠评估工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In Europe, the mean incidence of urinary tract infections in intensive care units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is estimated to give additional health-care costs of £1-2.5 billion in the United Kingdom alone. This is in sharp contrast to the low cost of urinary catheters and emphasizes the need for innovative products that reduce the incidence rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar problems. Antimicrobial strategies are being developed, however, the evaluation of their efficacy is very challenging. This review aims to provide considerations and recommendations covering all relevant aspects of antimicrobial material testing, including surface characterization, biocompatibility, cytotoxicity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic conditions, all in the perspective of complying to the complex pathology of device-associated urinary tract infection. The recommendations should be on the basis of standard assays to be developed which would enable comparisons of results obtained in different research labs both in industry and in academia, as well as provide industry and academia with tools to assess the antimicrobial properties for urinary tract devices in a reliable way.
参考来源
- Ramstedt M, Ribeiro IAC, Bujdakova H, et al. Evaluating Efficacy of Antimicrobial and Antifouling Materials for Urinary Tract Medical Devices: Challenges and Recommendations. Macromol Biosci. 2019. PMID: 30884146. doi:10.1002/mabi.201800384
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。